A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate

Simple item page
dc.contributor.authorRomero, Roberto
dc.contributor.authorNien, Jyh Kae
dc.contributor.authorEspinoza, Jimmy
dc.contributor.authorTodem, David
dc.contributor.authorFu, Wenjiang
dc.contributor.authorChung, Hwan
dc.contributor.authorKusanovic, Juan Pedro
dc.contributor.authorGotsch, Francesca
dc.contributor.authorErez, Offer
dc.contributor.authorMazaki Tovi, Shali
dc.contributor.authorGomez, Ricardo
dc.contributor.authorEdwin, Sam
dc.contributor.authorChaiworapongsa, Tinnakorn
dc.contributor.authorLevine, Richard J.
dc.contributor.authorKarumanchi, S. Ananth
dc.date.accessioned2024-01-10T13:11:00Z
dc.date.available2024-01-10T13:11:00Z
dc.date.issued2008
dc.description.abstractIntroduction. Accumulating evidence suggests that an imbalance between pro-angiogenic (i.e., vascular endothelial growth factor (VEGF) and placental growth factor (PlGF)) and anti-angiogenic factors (i.e., soluble VEGF receptor-1 (sVEGFR-1, also referred to as sFlt1)) is involved in the pathophysiology of preeclampsia (PE). Endoglin is a protein that regulates the pro-angiogenic effects of transforming growth factor , and its soluble form has recently been implicated in the pathophysiology of PE. The objective of this study was to determine if changes in maternal plasma concentration of these angiogenic and anti-angiogenic factors differ prior to development of disease among patients with normal pregnancies and those destined to develop PE (preterm and term) or to deliver a small for gestational age (SGA) neonate.
dc.description.abstractMethods. This longitudinal nested case-control study included 144 singleton pregnancies in the following groups: (1) patients with uncomplicated pregnancies who delivered appropriate for gestational age (AGA) neonates (n=46); (2) patients who delivered an SGA neonate but did not develop PE (n=56); and (3) patients who developed PE (n=42). Longitudinal samples were collected at each prenatal visit, scheduled at 4-week intervals from the first or early second trimester until delivery. Plasma concentrations of soluble endoglin (s-Eng), sVEGFR-1, and PlGF were determined by specific and sensitive ELISA.
dc.description.abstractResults. (1) Patients destined to deliver an SGA neonate had higher plasma concentrations of s-Eng throughout gestation than those with normal pregnancies; (2) patients destined to develop preterm PE and term PE had significantly higher concentrations of s-Eng than those with normal pregnancies at 23 and 30 weeks, respectively (for preterm PE: p0.036 and for term PE: p=0.002); (3) patients destined to develop PE (term or preterm) and those who delivered an SGA neonate had lower plasma concentrations of PlGF than those with a normal pregnancy throughout gestation, and the maternal plasma concentration of this analyte became detectable later among patients with pregnancy complications, compared to normal pregnant women; (4) there were no significant differences in the plasma concentrations of sVEGFR-1 between patients destined to deliver an SGA neonate and those with normal pregnancies; (5) patients destined to develop preterm and term PE had a significantly higher plasma concentration of sVEGFR-1 at 26 and 29 weeks of gestation than controls (p=0.009 and p=0.0199, respectively); and (6) there was no significant difference in the increment of sVEGFR-1 between control patients and those who delivered an SGA neonate (p=0.147 at 25 weeks and p=0.8285 at 40 weeks).
dc.description.abstractConclusions. (1) Changes in the maternal plasma concentration of s-Eng, sVEGFR-1, and PlGF precede the clinical presentation of PE, but only changes in s-Eng and PlGF precede the delivery of an SGA neonate; and (2) differences in the profile of angiogenic and anti-angiogenic response to intrauterine insults may determine whether a patient will deliver an SGA neonate, develop PE, or both.
dc.description.funderIntramural NIH HHS
dc.description.funderEUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT
dc.description.funderEUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT
dc.fechaingreso.objetodigital2024-05-09
dc.format.extent18 páginas
dc.fuente.origenWOS
dc.identifier.doi10.1080/14767050701830480
dc.identifier.eissn1476-4954
dc.identifier.issn1476-7058
dc.identifier.pubmedidMEDLINE:18175241
dc.identifier.urihttps://doi.org/10.1080/14767050701830480
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/77976
dc.identifier.wosidWOS:000252342700003
dc.information.autorucMedicina;Gómez R;S/I;80926
dc.issue.numero1
dc.language.isoen
dc.nota.accesocontenido parcial
dc.publisherTAYLOR & FRANCIS LTD
dc.revistaJOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE
dc.rightsacceso restringido
dc.subjectintrauterine growth restriction
dc.subjectplacental disease
dc.subjectSGA
dc.subjectIUGR
dc.subjectpreterm birth
dc.subjectsoluble Flt-1
dc.subjectlongitudinal
dc.subjectgrowth curve model
dc.subjectpregnancy
dc.subjectUTERINE ARTERY DOPPLER
dc.subjectCIRCULATING ANTIANGIOGENIC FACTORS
dc.subjectUTEROPLACENTAL BLOOD-FLOW
dc.subjectHUMAN BONE-MARROW
dc.subjectTYROSINE KINASE-1
dc.subjectMIRROR-SYNDROME
dc.subjectSERUM-LEVELS
dc.subjectFACTOR-BETA
dc.subjectCELLULAR-RESPONSES
dc.subjectOXIDATIVE STRESS
dc.subject.ods03 Good Health and Well-being
dc.subject.ods05 Gender Equality
dc.subject.odspa03 Salud y bienestar
dc.subject.odspa05 Igualdad de género
dc.titleA longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate
dc.typeartículo
dc.volumen21
sipa.codpersvinculados80926
sipa.indexWOS
sipa.indexScopus
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2024-05-09. A longitudinal study of angiogenic and anti-angiogenic factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate.pdf
Size:
4.01 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas